XBiotech Inc. (NASDAQ:XBIT) VP Queena Han sold 19,573 shares of the firm’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $15.00, for a total transaction of $293,595.00. Following the sale, the vice president now owns 19,573 shares of the company’s stock, valued at approximately $293,595. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Queena Han also recently made the following trade(s):

  • On Thursday, September 8th, Queena Han sold 427 shares of XBiotech stock. The stock was sold at an average price of $15.00, for a total transaction of $6,405.00.

Shares of XBiotech Inc. (NASDAQ:XBIT) opened at 15.01 on Monday. XBiotech Inc. has a 52 week low of $6.36 and a 52 week high of $25.00. The stock’s 50 day moving average is $13.93 and its 200 day moving average is $14.73. The stock’s market cap is $487.27 million.

XBiotech (NASDAQ:XBIT) last posted its quarterly earnings data on Monday, November 14th. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.08. On average, equities analysts forecast that XBiotech Inc. will post ($1.70) EPS for the current year.

Large investors have recently bought and sold shares of the company. BlackRock Fund Advisors raised its stake in XBiotech by 68.2% in the second quarter. BlackRock Fund Advisors now owns 871,482 shares of the biopharmaceutical company’s stock valued at $18,231,000 after buying an additional 353,253 shares during the last quarter. State Street Corp raised its stake in XBiotech by 508.7% in the second quarter. State Street Corp now owns 246,878 shares of the biopharmaceutical company’s stock valued at $5,164,000 after buying an additional 206,318 shares during the last quarter. Cadian Capital Management LP acquired a new stake in XBiotech during the third quarter valued at approximately $1,882,000. BlackRock Institutional Trust Company N.A. raised its stake in XBiotech by 396.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 168,693 shares of the biopharmaceutical company’s stock valued at $3,529,000 after buying an additional 134,692 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in XBiotech by 26.6% in the second quarter. Vanguard Group Inc. now owns 502,618 shares of the biopharmaceutical company’s stock valued at $10,515,000 after buying an additional 105,511 shares during the last quarter. 9.74% of the stock is currently owned by institutional investors and hedge funds.

Separately, Zacks Investment Research upgraded shares of XBiotech from a “hold” rating to a “buy” rating and set a $17.00 price target for the company in a research note on Saturday.

About XBiotech

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

5 Day Chart for NASDAQ:XBIT

Receive News & Stock Ratings for XBiotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech Inc. and related stocks with our FREE daily email newsletter.